Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature

被引：5

作者：

Shibata, Osamu ^{[1
]}

Kamimura, Kenya ^{[1
]}

Ko, Masayoshi ^{[1
]}

Sakai, Norihiro ^{[1
]}

Abe, Hiroyuki ^{[1
]}

Morita, Shinichi ^{[1
]}

Mizusawa, Takeshi ^{[1
]}

Sato, Hiroki ^{[1
]}

Sakamaki, Akira ^{[1
]}

Terai, Shuji ^{[1
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Gastroenterol & Hepatol, Niigata, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 11期

关键词：

hepatocellular carcinoma; FGFR4; FGF19; lenvatinib; molecular targeting agents; CANCER; ANGIOGENESIS; SORAFENIB; FGF19; INHIBITOR; PROGNOSIS; XENOGRAFT;

D O I：

10.2169/internalmedicine.6580-20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Basic and clinical research have shown that the expression of molecules involved in the hepatocellular carcinoma (HCC) cell signaling pathway is related to the sensitivity to molecular-targeted agents. We herein report a case of HCC that was effectively treated with lenvatinib after a poor response to sorafenib. The tumor showed a high expression of fibroblast growth factor receptor 4, which is reportedly related to the sensitivity to lenvatinib in vitro. The information obtained from this case and from our literature review highlights the importance of assessing the expression of the molecules involved in tumors for effective precision medicine.

引用

页码：1709 / 1715

页数：7

共 36 条

[31] Global Cancer Statistics, 2012 [J].

Torre, Lindsey A. ;

Bray, Freddie ;

Siegel, Rebecca L. ;

Ferlay, Jacques ;

Lortet-Tieulent, Joannie ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (02) :87-108

[32] FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation [J].

Wu, Xinle ;

Ge, Hongfei ;

Lemon, Bryan ;

Vonderfecht, Steven ;

Weiszmann, Jennifer ;

Hecht, Randy ;

Gupte, Jamila ;

Hager, Todd ;

Wang, Zhulun ;

Lindberg, Richard ;

Li, Yang .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (08) :5165-5170

[33] Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage [J].

Yamamoto, Yuji ;

Matsui, Junji ;

Matsushima, Tomohiro ;

Obaishi, Hiroshi ;

Miyazaki, Kazuki ;

Nakamura, Katsuji ;

Tohyama, Osamu ;

Semba, Taro ;

Yamaguchi, Atsumi ;

Hoshi, Sachi Suzuki ;

Mimura, Fusayo ;

Haneda, Toru ;

Fukuda, Yoshio ;

Kamata, Jun-ichi ;

Takahashi, Keiko ;

Matsukura, Masayuki ;

Wakabayashi, Toshiaki ;

Asada, Makoto ;

Nomoto, Ken-ichi ;

Watanabe, Tatsuo ;

Dezso, Zoltan ;

Yoshimatsu, Kentaro ;

Funahashi, Yasuhiro ;

Tsuruoka, Akihiko .

VASCULAR CELL, 2014, 6

[34]

Yamauchi M, 2020, CLIN TRANSL GASTROEN, V11

[35] A global view of hepatocellular carcinoma: trends, risk, prevention and management [J].

Yang, Ju Dong ;

Hainaut, Pierre ;

Gores, Gregory J. ;

Amadou, Amina ;

Plymoth, Amelie ;

Roberts, Lewis R. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (10) :589-604

[36] FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β-catenin signaling cascade via FGFR4 activation [J].

Zhao, Huakan ;

Lv, Fenglin ;

Liang, Guizhao ;

Huang, Xiaobin ;

Wu, Gang ;

Zhang, Wenfa ;

Yu, Le ;

Shi, Lei ;

Teng, Yong .

ONCOTARGET, 2016, 7 (12) :13575-13586

← 1 2 3 4 →